Results 61 to 70 of about 10,024 (235)

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial : A Randomized, Placebo-Controlled Trial [PDF]

, 2023
Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants' self-reported symptoms in the MOVe-OUT trial ...
Brotons, Carlos, Brown, Michelle, Coetzee, Kathleen, De Anda, Carisa, Du, Jiejun, Guan, Yanfen, Johnson, Matthew G., Kozlov, Roman, Lopez, Rudy, Norquist, Josephine M., Paschke, Amanda, Puenpatom, Amy, Santiaguel, Joel, Surber, Joseph, Universitat Autònoma de Barcelona, Weinberg, Aaron, Williams-Diaz, Angela, Zhang, Ying, Zhao, Yujie   +18 more
core   +1 more source

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Metabolites, 2023
The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19.
Divya Teli, Pankti Balar, Kishan Patel, Anu Sharma, Vivek Chavda, Lalit Vora   +5 more
doaj   +1 more source

Equipoise, standard of care, and consent: Responding to the authorisation of new COVID-19 treatments in randomised controlled trials [PDF]

, 2022
In response to the COVID-19 pandemic, large-scale research and pharmaceutical regulatory processes have proceeded at a dramatically increased pace with new and effective, evidence-based COVID-19 interventions rapidly making their way into the clinic ...
Dal-Ré, Rafael, Holm, Søren, Lewis, Jonathan   +2 more
core   +4 more sources

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences

Bulletin of the National Research Centre, 2022
Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj   +1 more source

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

Aging and Health Research, 2023
Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Kohei Fujita, Osamu Kanai, Hiroaki Hata, Kenjiro Ishigami, Kazutaka Nanba, Naoki Esaka, Koichi Seta, Tadashi Mio, Takao Odagaki   +8 more
doaj   +1 more source

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2. [PDF]

J Clin Invest
Molnupiravir is an antiviral medicine that induces lethal copying errors during SARS-CoV-2 RNA replication. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials ...
Esmaeili S, Owens K, de Leon UA, Standing JF, Lowe DM, Zhang S, Watson JA, Schilling WH, Wagoner J, Polyak SJ, Schiffer JT.   +10 more
europepmc   +2 more sources

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19

The Lancet Regional Health. Western Pacific, 2023
Summary: Background: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19.
Abraham Ka-Chung Wai, Crystal Ying Chan, Annie Wai-Ling Cheung, Kailu Wang, Sunny Ching-Long Chan, Teddy Tai-Loy Lee, Luke Yik-Fung Luk, Edmond Tsz-Fung Yip, Joshua Wing-Kei Ho, Omar Wai-Kiu Tsui, Kelly Wing-Yin Cheung, Shiyeow Lee, Chak-kwan Tong, Tafu Yamamoto, Timothy Hudson Rainer, Eliza Lai-Yi Wong   +15 more
doaj   +1 more source

SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir [PDF]

, 2023
SARS-CoV-2 infection; Transplant recipients; Solid organInfecció per SARS-CoV-2; Receptors de trasplantament; Òrgans sòlidsInfección por SARS-CoV-2; Receptores de trasplantes; Órganos sólidosSolid organ transplant recipients (SOTR) constitute one of the ...
Len, Oscar, Villamarín Melio, Miguel
core   +1 more source

Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]

, 2022
BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori, Alessandro, Cozzi Lepri, Andrea, Antinori, AnnaRosa, Garbuglia, Claudia, Cimaglia, Eleonora, Lalle, Emanuela, Caraffa, Emanuele, Nicastri, Enrico, Girardi, Eugenia, Milozzi, Fabrizio, Carletti, Fabrizio, Maggi, Francesca, Colavita, Francesco, Vaia, Gaetano, Maffongelli, Ilaria, Mastrorosa, INMI COVID-19 Outpatient Treatment Study Group, Jessica, Paulicelli, Lavinia, Fabeni, Pierluca, Piselli, Raffaella, Libertone, Serena, Vita, Silvia, Rosati, Simone, Lanini, Valentina, Mazzotta   +24 more
core   +2 more sources

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics, 2021
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko   +2 more
doaj   +1 more source